Liminal BioSciences Inc. LMNL
Set alert
As of Sep 25, 3:59 PM ET
52-week range unavailable
- Open
- 8.48
- Prev close
- 8.50
- Mkt cap
- 26.04M
- Vol
- 5.05K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.48
- High
- 8.50
- Forward P/E
- -0.92
- Beta
- 29.84
- Short ratio
- 4.03
- Inst. own
- 0.59%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 8, 2023
- 50-d avg
- 6.68
- 200-d avg
- 5.28
- 1y target
- 7.53
Key statistics
- Market cap
- 26.04M
- Enterprise value
- 273.17K
- Trailing P/E
- 0.00
- Forward P/E
- -0.92
- PEG ratio
- 0.00
- Price / sales
- 48.50
- Price / book
- 0.90
- EPS (TTM)
- -8.83
- Beta
- 29.84
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 702.61%
- Revenue (TTM)
- 537.00K
- Revenue growth
- 0.00%
- Free cash flow
- -25.90M
- Total cash
- 26.94M
- Total debt
- 1.36M
- Return on equity
- -96.58%
- Shares outstanding
- 3.10M
- Short % of float
- 2.57%
- 50-day average
- 6.68
- 200-day average
- 5.28
Analyst view
Consensus: hold
Next earnings
Nov 8, 2023
Expected Nov 8, 2023. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 8, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 8, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| May 9, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| Mar 15, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Nov 9, 2022 | Sep 1, 2022 | 0.00 | — | — | — |
| Aug 9, 2022 | Jun 1, 2022 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 24, 2021 | HC Wainwright & Co. | down | Buy | Neutral |
| Jun 2, 2021 | Piper Sandler | down | Overweight | Neutral |
| Feb 18, 2021 | HC Wainwright & Co. | init | — | Buy |
| Dec 21, 2020 | Piper Sandler | init | — | Overweight |
About Liminal BioSciences Inc.
Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- liminalbiosciences.com
News
- LIMINAL BIOSCIENCES ANNOUNCES COMPLETION OF THE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP
- LIMINAL BIOSCIENCES RECEIVES FINAL COURT ORDER FOR PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP
- LIMINAL BIOSCIENCES SHAREHOLDERS APPROVE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP
- LIMINAL BIOSCIENCES FILES AMENDED SCHEDULE 13E-3 AND SUPPLEMENT TO THE MANAGEMENT INFORMATION CIRCULAR
- LIMINAL BIOSCIENCES OBTAINS INTERIM ORDER FOR PROPOSED ARRANGEMENT WITH STRUCTURED ALPHA LP
- Liminal (LMNL) Up 40% on Buyout Offer From Majority Shareholder
- Liminal BioSciences stock rockets on take-private deal with a fund managed by Thomvest Asset Management
- Liminal BioSciences Announces Arrangement Agreement with Structured Alpha LP
- Why SeaChange International Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket
- Why Kura Sushi Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Your note
Sign in to keep a note on LMNL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Best (Simon Geoffrey) | Director of Issuer | Acquisition or disposition in the public market | Mar 23, 2022 | 0 |
| Iskra, Marie | Senior Officer of Issuer | Acquisition or disposition in the public market | Sep 11, 2022 | 0 |
| Wach (Timothy Steven) | Director of Issuer | Acquisition or disposition in the public market | Mar 21, 2022 | 200 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Susquehanna International Group, LLP | 0.46% | 14,133 | 118.58K | Mar 30, 2023 |
| National Bank of Canada/FI | 0.32% | 9,853 | 82.67K | Mar 30, 2023 |
| Estabrook Capital Management | 0.02% | 500 | 4.20K | Mar 30, 2023 |
| Royal Bank of Canada | 0.02% | 502 | 4.21K | Mar 30, 2023 |
| UBS Group AG | 0.00% | 48 | 402 | Mar 30, 2023 |
| Tanaka Capital Management Inc | 0.00% | 1 | 8 | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.07% | 2,273 | 19.07K | Feb 27, 2023 |